Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects
- 1Division of Nephrology and Immunology, RWTH University, Aachen, Germany
- 2Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany
- 3Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany
- 4Renal Unit, Department of Medicine II, Klinikum Rechts der Isar, Technical University, Munich, Germany
- 5Department of Pathology, Ludwig-Maximilians-University, Munich, Germany
- Correspondence to: Dr Holger Schmid Medizinische Poliklinik, Ludwig-Maximilians-Universität München, Pettenkoferstr 8a, 80336 Munich, Germany; holger.schmid{at}lrz.uni-muenchen.de
- Received 1 February 2006
- Accepted 11 August 2006
Abstract
Cryoglobulinaemia may cause cutaneous vasculitis and glomerulonephritis, potentially leading to end stage renal failure. An important proportion of cryoglobulinaemias are secondary to hepatitis C virus infection. Emerging antiviral treatment options offer a chance for causal therapy of these cases of cryoglobulinaemia. This review summarises the classification and clinical and therapeutic aspects of cryoglobulinaemic vasculitis and glomerulonephritis.
- ANCA, antineutrophil cytoplasmic antibody
- HBV, hepatitis B virus
- HCV, hepatitis C virus
- MPGN, membranoproliferative glomerulonephritis
Footnotes
-
Funding: None.
-
Competing interests: None.







